Riociguat in Patients With Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
Status:
No longer available
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The aim of the study is to assess safety, tolerability and clinical effects of different
doses of riociguat in patients with inoperable Chronic Thromboembolic Pulmonary Hypertension
(CTEPH) and who are not satisfactorily treated and cannot participate in any other CTEPH
trial. In the US the study runs as an Expanded Access program under 21 CFR 312.320.